A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni C., Comberiati P., Giovannini M., Agache I., Akdis M., Alves-Correia M., ...Daha Fazla

ALLERGY, cilt.75, sa.10, ss.2503-2541, 2020 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 75 Sayı: 10
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/all.14449
  • Dergi Adı: ALLERGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2503-2541
  • Anahtar Kelimeler: allergy, coronavirus disease 2019, COVID-19, SARS-CoV-2, severe acute respiratory syndrome-related coronavirus 2, ACUTE RESPIRATORY SYNDROME, ANGIOTENSIN-CONVERTING ENZYME, KAWASAKI-LIKE DISEASE, SARS-CORONAVIRUS, LONGITUDINAL PROFILE, SPIKE GLYCOPROTEIN, IMMUNE-RESPONSES, MANAGEMENT, EPIDEMIC, ASTHMA
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in similar to 9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.